Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands

In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.

Cancer Business Strategies ImmunoOncology

Cipla Claims Pricing Advantage For Albuterol In US

Cipla, which expects to enter the US albuterol inhalation market later this year, believes that it has the cost competitiveness to price “significantly lower” than competition and take a “fair share” of a market that recently saw the arrival of authorized generics.

Commercial Strategy Pricing Strategies

Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals

Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.

Commercial Exec Chat Rare Diseases
Advertisement


 Recent Tweets from Scrip


Embedding Time-Critical Scheduling in Drug Production

Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.

Download Whitepaper
Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

Santhera Shores Up Finances With Chiesi Deal for Raxone

In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.

Rare Diseases Companies Ophthalmic

Targovax Pivots Towards Oncolytic Viruses

Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.

 

Cancer ImmunoOncology Research & Development

GSK Revamps Sales Reps Incentives To Be Competitive In Cancer

Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.

Business Strategies Commercial

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

ElevateBio Announces AlloVir As First Spoke In Its Cell And Gene Therapy Hub

ElevateBio revealed the first company to hitch up with its newly established centralized cell and gene therapy development, manufacturing and commercial capabilities – AlloVir, formerly ViraCyte, which is developing T-cell therapies to treat viruses in immunocompromised patients.

Financing StartUps and SMEs

Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution

Amgen offered to buy its Scandinavian discovery partner for $166.8m to gain access to Nuevolution’s DNA-encoded drug discovery platform and nascent pipeline.

Commercial Companies

Lupin To Draw On Efficiencies As Japan Pricing Pressures Build

Pricing pressure in Japan is expected to weigh significantly on growth even in the generics segment, putting the focus on manufacturing and R&D efficiencies to sustain progress in this market, according to senior Lupin executives.

Commercial Strategy

Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio

Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.

Deals M & A

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

China Forced Tech Transfer Still A Problem, EU Firms Say

One in five European pharma companies and medical devices makers has been forced to transfer technologies in China, a fact which is “highly concerning” says the latest business survey report from an EU trade group in the country.

China Intellectual Property Market Intelligence

AZ, Takeda, Novartis Praised For Medicines Access Work But More Is Needed

The 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing, says a new report from the Access to Medicine Foundation.

International Pricing Strategies

Basilea-Pfizer’s Cresemba Heads For Indian Debut

Basilea’s Cresemba appears on course to a debut in India and partner Pfizer expects the novel antifungal to bolster its existing portfolio in the segment. Pricing of the product will be keenly watched.

Policy & Regulation India

Pediatric Oncology Advances Could Prompt More FDA-Required Studies

Findings being presented at ASCO next month could signify major increase in targets relevant to pediatric oncology, meaning sponsors should prepare for more US FDA-required studies under the RACE for Children legislation.

Pediatrics Cancer

Research & Development Explore this Topic

Set Alert for Research & Development

BIO-Europe Spring 2019: Newcomer Tubulis Tackles ADC Technology Shortcomings

Newly established Tubulis has been set up to generate protein-drug conjugates using a novel platform approach deriving from two German academic institutes. CEO Dominik Schumacher spoke to Mike Ward at BIO-Europe Spring 2019.

Platform Technologies StartUps and SMEs Research & Development

In Immunology, J&J Makes A Big Move On Biologic Combinations

The company has initiated a Phase II study of Tremfya and Simponi in combination for the treatment of ulcerative colitis, J&J's first human study of two targeted immunology drugs together. 
Biologics Clinical Trials

Pipeline Watch: Phase III Starts For Nirogacestat, Etrasimod

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

BIO-Europe Spring 2019: Modra Pharmaceuticals CEO On Enhancing Taxanes

Modra Pharmaceuticals’ three goals are to improve the toxicity, the efficacy and the formulation of taxane chemotherapies used to treat cancer. CEO Colin Freund spoke to Mike Ward.

Research and Development Strategies Research & Development
UsernamePublicRestriction

Register

Advertisement